Effect of Lamivudine on the Rat Pregnancy Outcome
Human immunodeficiency virus (HIV) infection is in growing incidence throughout the world. Due to the increasing proportion of affected women in reproductive years, the association of pregnancy with HIV infection becomes a matter of major Public Health concern. Antiretroviral drug administration tur...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Lenguaje: | English |
| Publicado: |
Sociedad Chilena de Anatomía
2005
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-95022005000300001 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Human immunodeficiency virus (HIV) infection is in growing incidence throughout the world. Due to the increasing proportion of affected women in reproductive years, the association of pregnancy with HIV infection becomes a matter of major Public Health concern. Antiretroviral drug administration turned out to be imperative during pregnancy in order to prevent the vertical transmission; accordingly, new antiretroviral drugs and anti-HIV drug associations have been tested in experimental pregnancy models before they are approved to be included in protocols for use during human pregnancy. Lamivudine is a nucleoside reverse transcriptase inhibitor currently used in association with other antiretrovirals. Since no data exist on the perinatal safety of lamivudine alone, as it is used in combination with other antiretroviral agents, and, until now, only preliminary data on the lamivudine-zidovudine combination were available, we decided to examine the gross maternal and fetal effects of lamivudine administered alone during the entire period of rat pregnancy. Forty pregnant animals were assigned at random to 4 groups (G1, G2, G3 and G4). G1 received drug vehicle; G2, G3 and G4 received daily oral doses of 5, 15 or 45 mg/kg of lamivudine, respectively. Rats were weighed on days 0, 7, 14 and 20 of pregnancy. On day 20 they were killed, their fetuses and placentas counted and weighed. The body weight gain of the rats was that normally expected for the gestation progression; no differences were noticed among the groups. In addition, no effects were observed regarding the fetal or placental number and weight, nor in the number of implantations, reabsortions, fetal or maternal deaths. In conclusion, the adverse effects reported for the lamivudine-zidovudine combination therapy may well be not due to lamivudine; further research involving a variety of strategies is needed to definitively ascertain the safety of that combination for preventing maternal-infant HIV transmission |
|---|